SG11201909783VA - Inhibitors and antagonists of gpr84 for the treatment of endometriosis - Google Patents

Inhibitors and antagonists of gpr84 for the treatment of endometriosis

Info

Publication number
SG11201909783VA
SG11201909783VA SG11201909783VA SG11201909783VA SG 11201909783V A SG11201909783V A SG 11201909783VA SG 11201909783V A SG11201909783V A SG 11201909783VA SG 11201909783V A SG11201909783V A SG 11201909783VA
Authority
SG
Singapore
Prior art keywords
international
gpr84
endometriosis
pct
rule
Prior art date
Application number
Other languages
English (en)
Inventor
Frank Sacher
Maik Obendorf
Gernot Langer
Estrada Martinez
Udo Oppermann
Catherine Shang
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of SG11201909783VA publication Critical patent/SG11201909783VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201909783V 2017-05-16 2018-05-15 Inhibitors and antagonists of gpr84 for the treatment of endometriosis SG11201909783VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17171351.4A EP3403649A1 (fr) 2017-05-16 2017-05-16 Inhibiteurs et antagonistes de gpr84 pour le traitement de l'endométriose
PCT/EP2018/062544 WO2018210822A1 (fr) 2017-05-16 2018-05-15 Inhibiteurs et antagonistes de gpr84 pour le traitement de l'endométriose

Publications (1)

Publication Number Publication Date
SG11201909783VA true SG11201909783VA (en) 2019-11-28

Family

ID=58745052

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909783V SG11201909783VA (en) 2017-05-16 2018-05-15 Inhibitors and antagonists of gpr84 for the treatment of endometriosis

Country Status (14)

Country Link
US (1) US20210401823A1 (fr)
EP (2) EP3403649A1 (fr)
JP (1) JP2020519662A (fr)
KR (1) KR20200003830A (fr)
CN (1) CN110573146A (fr)
AR (1) AR111801A1 (fr)
AU (1) AU2018269328A1 (fr)
BR (1) BR112019023999A2 (fr)
CA (1) CA3063489A1 (fr)
MX (1) MX2019013734A (fr)
PE (1) PE20191746A1 (fr)
SG (1) SG11201909783VA (fr)
TW (1) TW201900214A (fr)
WO (1) WO2018210822A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111012782B (zh) * 2019-12-27 2023-08-04 郑州大学第一附属医院 一种g蛋白偶联受体gpr84抑制剂及其应用
WO2021173660A1 (fr) * 2020-02-25 2021-09-02 The Texas A&M University System Méthodes de traitement de l'endométriose

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
DE60301953T2 (de) 2002-03-05 2006-07-27 Artemis Pharmaceuticals Gmbh Durch inzucht erzeugte von embryonalen stammzellen abgeleitete mäuse
GB0414798D0 (en) * 2004-07-01 2004-08-04 Paradigm Therapeutics Ltd Receptor
WO2007027661A2 (fr) 2005-09-02 2007-03-08 Arena Pharmaceuticals, Inc. Utilisation du recepteur humain couple aux proteines g et de ses modulateurs pour le traitement de l'atherosclerose et de troubles atherosclerotiques, et d'etats lies a l'expression du mcp-1
AR056142A1 (es) 2005-10-21 2007-09-19 Amgen Inc Metodos para generar el anticuerpo igg monovalente
AR089284A1 (es) * 2011-12-22 2014-08-13 Galapagos Nv Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios
GB201122146D0 (en) 2011-12-22 2012-02-01 Galapagos Nv Screening methods to identify compounds useful in the prevention and/or treatment of inflammatory conditions
US9708312B2 (en) 2012-12-20 2017-07-18 Galapagos Nv Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (GPR84 antagonists)
GB201411241D0 (en) 2014-06-25 2014-08-06 Galapagos Nv Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201506894D0 (en) 2015-04-23 2015-06-10 Galapagos Nv Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
EP3624781A1 (fr) 2020-03-25
US20210401823A1 (en) 2021-12-30
TW201900214A (zh) 2019-01-01
WO2018210822A1 (fr) 2018-11-22
CA3063489A1 (fr) 2018-11-22
CN110573146A (zh) 2019-12-13
MX2019013734A (es) 2020-01-15
KR20200003830A (ko) 2020-01-10
BR112019023999A2 (pt) 2020-06-30
AU2018269328A1 (en) 2019-11-07
JP2020519662A (ja) 2020-07-02
PE20191746A1 (es) 2019-12-12
AR111801A1 (es) 2019-08-21
EP3403649A1 (fr) 2018-11-21

Similar Documents

Publication Publication Date Title
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201907451XA (en) Substituted imidazo-quinolines as nlrp3 modulators
SG11201810697QA (en) Chimeric antigen receptor and car-t cells that bind bcma
SG11201809082WA (en) Nlrp3 modulators
SG11201900799XA (en) Pyridopyrimdinone cdk2/4/6 inhibitors
SG11201909646TA (en) Trem2 antigen binding proteins and uses thereof
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201906192SA (en) Methods of treating cancer with anti-pd-1 antibodies
SG11201408261UA (en) Syringe
SG11201806401YA (en) G protein-coupled receptor (gpcr) modulation by imipridones
SG11201808686VA (en) Synthesis of indazoles
SG11201906959RA (en) Aryl hydrocarbon receptor (ahr) modulator compounds
SG11201408279QA (en) Social sharing of security information in a group
SG11201908784TA (en) Improved antigen binding receptor formats
SG11201906958TA (en) Aryl hydrocarbon receptor (ahr) modulator compounds
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201809252YA (en) Methods for determining dpp3 and therapeutic methods
SG11201810429UA (en) Anti-cd19 antibody formulations
SG11201808106YA (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201408383SA (en) Methods of detecting diseases or conditions using circulating diseased cells
SG11201907364WA (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
SG11201909003YA (en) Integrated vascular access device and anchor pad
SG11201805755SA (en) Methods of administering hepcidin
SG11201408808WA (en) Method and system for treatment of biological tissue